Uncategorized

New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)

by Business Wire • 2021/04/16 • 0 Comments

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting.

Full Story →

← New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology

Sweat Sensor Warns of Impending COVID-19 Cytokine Storm →

Post navigation